Endometriosis Treatment Market Size to Hit USD 5.74 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Endometriosis Treatment Market

5.1. COVID-19 Landscape: Endometriosis Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Endometriosis Treatment Market, By Drug Type

8.1. Endometriosis Treatment Market Revenue and Volume, by Drug Type

8.1.1. Hormonal Therapy

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Non-Hormonal Therapy

8.1.2.1. Market Revenue and Volume Forecast

Chapter 9. Global Endometriosis Treatment Market, By Route of Administration

9.1. Endometriosis Treatment Market Revenue and Volume, by Route of Administration

9.1.1. Oral

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Injectables

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Nasal

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Others (e.g., implants, transdermal patches)

9.1.4.1. Market Revenue and Volume Forecast

Chapter 10. Global Endometriosis Treatment Market, By Surgery Type

10.1. Endometriosis Treatment Market Revenue and Volume, by Surgery Type

10.1.1. Conservative Surgery

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Definitive Surgery

10.1.2.1. Market Revenue and Volume Forecast

Chapter 11. Global Endometriosis Treatment Market, By Distribution Channel

11.1. Endometriosis Treatment Market Revenue and Volume, by Distribution Channel

11.1.1. Hospital Pharmacies

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Retail Pharmacies

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Volume Forecast

Chapter 12. Global Endometriosis Treatment Market, By End-User

12.1. Endometriosis Treatment Market Revenue and Volume, by End-User

12.1.1. Hospitals & Clinics

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Homecare

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Specialty Centers

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Others

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global Endometriosis Treatment Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Drug Type

13.1.2. Market Revenue and Volume Forecast, by Route of Administration

13.1.3. Market Revenue and Volume Forecast, by Surgery Type

13.1.4. Market Revenue and Volume Forecast, by Distribution Channel

13.1.5. Market Revenue and Volume Forecast, by End-User

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Drug Type

13.1.6.2. Market Revenue and Volume Forecast, by Route of Administration

13.1.6.3. Market Revenue and Volume Forecast, by Surgery Type

13.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel

13.1.6.5. Market Revenue and Volume Forecast, by End-User

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Drug Type

13.1.7.2. Market Revenue and Volume Forecast, by Route of Administration

13.1.7.3. Market Revenue and Volume Forecast, by Surgery Type

13.1.7.4. Market Revenue and Volume Forecast, by Distribution Channel

13.1.7.5. Market Revenue and Volume Forecast, by End-User

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Drug Type

13.2.2. Market Revenue and Volume Forecast, by Route of Administration

13.2.3. Market Revenue and Volume Forecast, by Surgery Type

13.2.4. Market Revenue and Volume Forecast, by Distribution Channel

13.2.5. Market Revenue and Volume Forecast, by End-User

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Drug Type

13.2.6.2. Market Revenue and Volume Forecast, by Route of Administration

13.2.6.3. Market Revenue and Volume Forecast, by Surgery Type

13.2.7. Market Revenue and Volume Forecast, by Distribution Channel

13.2.8. Market Revenue and Volume Forecast, by End-User

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Drug Type

13.2.9.2. Market Revenue and Volume Forecast, by Route of Administration

13.2.9.3. Market Revenue and Volume Forecast, by Surgery Type

13.2.10. Market Revenue and Volume Forecast, by Distribution Channel

13.2.11. Market Revenue and Volume Forecast, by End-User

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Drug Type

13.2.12.2. Market Revenue and Volume Forecast, by Route of Administration

13.2.12.3. Market Revenue and Volume Forecast, by Surgery Type

13.2.12.4. Market Revenue and Volume Forecast, by Distribution Channel

13.2.13. Market Revenue and Volume Forecast, by End-User

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Drug Type

13.2.14.2. Market Revenue and Volume Forecast, by Route of Administration

13.2.14.3. Market Revenue and Volume Forecast, by Surgery Type

13.2.14.4. Market Revenue and Volume Forecast, by Distribution Channel

13.2.15. Market Revenue and Volume Forecast, by End-User

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Drug Type

13.3.2. Market Revenue and Volume Forecast, by Route of Administration

13.3.3. Market Revenue and Volume Forecast, by Surgery Type

13.3.4. Market Revenue and Volume Forecast, by Distribution Channel

13.3.5. Market Revenue and Volume Forecast, by End-User

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Drug Type

13.3.6.2. Market Revenue and Volume Forecast, by Route of Administration

13.3.6.3. Market Revenue and Volume Forecast, by Surgery Type

13.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel

13.3.7. Market Revenue and Volume Forecast, by End-User

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Drug Type

13.3.8.2. Market Revenue and Volume Forecast, by Route of Administration

13.3.8.3. Market Revenue and Volume Forecast, by Surgery Type

13.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel

13.3.9. Market Revenue and Volume Forecast, by End-User

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Drug Type

13.3.10.2. Market Revenue and Volume Forecast, by Route of Administration

13.3.10.3. Market Revenue and Volume Forecast, by Surgery Type

13.3.10.4. Market Revenue and Volume Forecast, by Distribution Channel

13.3.10.5. Market Revenue and Volume Forecast, by End-User

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Drug Type

13.3.11.2. Market Revenue and Volume Forecast, by Route of Administration

13.3.11.3. Market Revenue and Volume Forecast, by Surgery Type

13.3.11.4. Market Revenue and Volume Forecast, by Distribution Channel

13.3.11.5. Market Revenue and Volume Forecast, by End-User

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Drug Type

13.4.2. Market Revenue and Volume Forecast, by Route of Administration

13.4.3. Market Revenue and Volume Forecast, by Surgery Type

13.4.4. Market Revenue and Volume Forecast, by Distribution Channel

13.4.5. Market Revenue and Volume Forecast, by End-User

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Drug Type

13.4.6.2. Market Revenue and Volume Forecast, by Route of Administration

13.4.6.3. Market Revenue and Volume Forecast, by Surgery Type

13.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel

13.4.7. Market Revenue and Volume Forecast, by End-User

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Drug Type

13.4.8.2. Market Revenue and Volume Forecast, by Route of Administration

13.4.8.3. Market Revenue and Volume Forecast, by Surgery Type

13.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel

13.4.9. Market Revenue and Volume Forecast, by End-User

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Drug Type

13.4.10.2. Market Revenue and Volume Forecast, by Route of Administration

13.4.10.3. Market Revenue and Volume Forecast, by Surgery Type

13.4.10.4. Market Revenue and Volume Forecast, by Distribution Channel

13.4.10.5. Market Revenue and Volume Forecast, by End-User

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Drug Type

13.4.11.2. Market Revenue and Volume Forecast, by Route of Administration

13.4.11.3. Market Revenue and Volume Forecast, by Surgery Type

13.4.11.4. Market Revenue and Volume Forecast, by Distribution Channel

13.4.11.5. Market Revenue and Volume Forecast, by End-User

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Drug Type

13.5.2. Market Revenue and Volume Forecast, by Route of Administration

13.5.3. Market Revenue and Volume Forecast, by Surgery Type

13.5.4. Market Revenue and Volume Forecast, by Distribution Channel

13.5.5. Market Revenue and Volume Forecast, by End-User

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Drug Type

13.5.6.2. Market Revenue and Volume Forecast, by Route of Administration

13.5.6.3. Market Revenue and Volume Forecast, by Surgery Type

13.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel

13.5.7. Market Revenue and Volume Forecast, by End-User

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Drug Type

13.5.8.2. Market Revenue and Volume Forecast, by Route of Administration

13.5.8.3. Market Revenue and Volume Forecast, by Surgery Type

13.5.8.4. Market Revenue and Volume Forecast, by Distribution Channel

13.5.8.5. Market Revenue and Volume Forecast, by End-User

Chapter 14. Company Profiles

14.1. AbbVie Inc.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Bayer AG

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Mayne Pharma Group Limited

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Pfizer Inc.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Teva Pharmaceuticals

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Merck & Co., Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. AstraZeneca plc

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Myovant Sciences

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Ferring Pharmaceuticals

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Takeda Pharmaceutical Company Limited

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global endometriosis treatment market is expected to increase from USD 1.79 billion in 2024 to USD 5.74 billion by 2034.

The endometriosis treatment market is expected to grow at a compound annual growth rate (CAGR) of around 12.35% from 2025 to 2034.

The major players in the endometriosis treatment market include AbbVie Inc., Bayer AG, Pfizer Inc., Merck & Co., Inc., AstraZeneca plc, Teva Pharmaceuticals, Myovant Sciences, Ferring Pharmaceuticals, Takeda Pharmaceutical Company Limited, and Mayne Pharma Group Limited.

The driving factors of the endometriosis treatment market are the development of novel treatment options, like targeted medication, immunomodulators, and non-hormonal treatments.

North America region will lead the global endometriosis treatment market during the forecast period 2025 to 2034.